NEW YORK-- Shares of Aveo Oncology sank Friday after the company said its partner Astellas won't ask European Union regulators to approve their kidney cancer pill tivozanib. The disclosure comes three weeks after a panel of Food and Drug Administration advisors recommended the drug not be approved because of its potential health risks.» Read More
As Congress, the FDA and the drugmakers wrestle with what appear to be impending warnings about the safety of Avandia, investors are wrestling with estimates of the collateral damage to this multi-billion dollar GlaxoSmithKline franchise. Some say it's the next Vioxx and that investors have priced into the stock a high likelihood that GSK will eventually pull the drug from the market. Others compare it to what happened with Pfizer's painkiller Celebrex in the wake of the Vioxx withdrawal.
John Tepichin says he's all in on his one stock--Biomarin--and "going for the fences," as the Million Dollar Portfolio Challenge is coming to a close. The contest ends Friday at the closing bell. John's stock was down some 2 percent today, but he says he has some "strong" ideas for Friday. He's currently in 15th place out of 20 finalists--so John better have some pretty good "fence going" ideas.
Big pharma analysts keep close tabs on prescription trends. Many of them issue weekly reports to clients about what's up, what's down, what's holding steady. Investors use the data as a leading indicator for what quarterly sales and profits might look like. So, check out what A.G. Edwards' Joe Tooley is writing in his most recent "Weekly Prescription Trends" report.Tooley titles it, "Lipitor Continues to Decline, Can Simvastatin (the generic version of Zocor) Surpass It?"
Good morning everyone. Today--Thursday--is a big day for our contestants. The trades they execute prior to 4pm will be the last trades that will impact their total portfolio value based on their performance on Friday. And, the race at the top gets tighter each day. Only $22K separates the top three positions. Nancy Beaumont holds first place for the 3rd straight day on the 9.75% gain of The Men's Wearhouse. Nancy looks like she may maintain her first position with Gymboree up almost 10% in extended hours.
In the middle of the Avandia blowup, GlaxoSmithKline this week is launching the new over-the-counter diet pill "Alli." The company says it's spending 150 million bucks on the first-year marketing of the formerly prescription-only Xenical from Roche.A big chunk of that is going toward a multi-pronged educational campaign to convince dieters they have to change their eating habits and exercise if they want to get the maximum benefit from Alli. That's crucial with this drug because the more fat you eat, the worse the gastrointestinal side effects. Clue: Glaxo is telling Alli users to wear dark pants and bring an extra pair to work. The company has gone so far as to set up an exhibit in New York City this week where people can get more information about Alli.
So, let's start with GlaxoSmithKline's Avandia. The stock is rebounding a little bit today after the pummeling it took yesterday. Once again, the New England Journal of Medicine study saw an "embargo break" by another media outlet. That means the news hit in the middle of the trading day yesterday, catching just about everyone by surprise. The embargo was supposed to have lifted at 5 p.m. ET yesterday, which would have given all of the stakeholders -- chiefly Glaxo -- the ability to issue their prepared press releases at the same time.
It sits there in front of you: a plate filled to the overflow point with chili -- and under it, two cheeseburger patties, fried potatoes and one egg, over easy.What are you about to do?
Here's our contest stock report for both the finals and Second Chance Showdown. Acxiom proved to be a winner for several finalsts--and you can see why. It was up 18%. But those who had ADS did even better as that stock was up 24% on news of a merger. Weak earnings took a toll on the worst performing stocks--while the most active and widely held reamined the same.
Good morning all. Big changes on the leaderboard for the contest finals. Steven Lee (that's his picture) jumps from 12th place on Wednesday to take the lead by gaining $182K with Acxiom Corp. which was up 18.08% Thursday. And Mary Williams continues her climb from 4th place Wednesday to take 2nd place--with another big gain on Ctrip.com that added $87K to her portfolio. Serge Amelyan falls into 4th place from first and Stephen Luchko is down in 6th place from 2nd.
Okay, we're slowly but surely posting the most recent information on the contest. Here's the stock report--for both the Million Dollar Portfolio Challenge and Second Chance Showdown. Earnings are still helping the best performers. One longtime favorite--CMGI--shows up on worst performer as well as most active and widely held. Maybe it's time has come and gone. Here ya go..
Good morning all. We have some info for you. The first Million Dollar Finals leader is Donald Tang who gained $73K on Mindray Medical. He's closely followed by Serge Amelyan with the same Mindray Medical trade. However, Serge used his remaining cash to buy 2 shares of CMGI at $2.44, which fell -2.46% Tuesday-- resulting in the $0.12 difference between him and Donald, and costing him the tie for first.
Friday--today--is the last day of Trading With The Stars--and only transactions that were input by 4 pm ET Thursday will make a difference in their standings. As the Dow fell almost 150 points, Ernie Hudson was the only celeb to show a portfolio gain Thursday--on Gmarket. Jonathan Tucker regained the top spot, and Stephen Collins fell back into second on heavy losses in Golden Telecom. Meanwhile, Chris Moneymaker got crushed on Allscripts Healthcare, which has cost him $181,862.60 since he purchased it on 5/8, and he is now in last place. James Cromwell was hit hard by Knot Inc. which cost him $160K dropping him from 4th to 8th.
Wow--can Stephen Collins pick em or not. As we mentioned in an earlier post on contest stocks--best performong stock Foster Wheeler let the actor soar into first place in Trading With The Stars--with a $78K gain on FWLT--which was up 19.96% Wednesday. He now has a total portfolio value of $1,237,825.31 which gives him a $14K lead over Jonathan Tucker with 2 days remaining in the contest. Lots of hooray's for Stephen from the "Morning Call" Team--the show he's playing for.
Well, our contest "stock report" has some interesting news. One of the best performers was a stock (FWLT) that celeb/actor Stephen Collins had on his list--and one that put him in the lead of Trading With The Stars (more on that in another post). In fact, it was the best of the best performers. And one pick that made the most actives, was one recommended yesterday by guest blogger Timothy Sykes--SIX. Here you go...
As I write this, Dendreon is about to cross the 100,000,000 trading volume threshold. If Cisco hadn't made news as well, DNDN would easily be the most active stock on any of the major exchanges today. Yesterday the FDA sent Dendreon what's called an "approvable letter". I've called it a euphemism for "delay", but essentially it means the agency says it might eventually approve a product if or when the company provides whatever other information it wants.
The top 4 celebrities remain constant with Jonathan Tucker holding onto his lead with only $62,581.29 separating him from Stephen Collins. Poker champion Moneymaker is betting on Allscripts Healthcare to move him up from 4th on strong earnings after the bell Tuesday. And Hall of Famer Johnny Bench is counting on American Oriental Bioengineering to continue to perform--as he's in 5th place.
Hey folks. Jeff Mishlove is here with his picks today. Let's get right to his post: This has been a very busy time for me, so I am submitting this blog a bit later than usual. However, the lateness allows me to see that the picks I recommended for yesterday are doing quite well. Two of the five are among the top two eligible stocks for the contest on Tuesday. Those are aQuantive and Blue Nile – up, as I am writing, 11.98% and 17.21% respectively.
We have an earnings video news report by CNBC/Wall Street Journal Editor Bob O'Brien. Bob looked at three companies--Disney, CVS Caremark and Molson-Coors. Disney reports after the bell today and CVS has already reported. Molson has yet to.
It's do or die time for our celebs as this is the final week of Trading With The Stars, so here are the standings. Jonathan tucker holds on to the lead with a total portfolio value of $1,198,400.00 which is down $25 from Thursday's total. Stephen Collins continues in the #2 spot with a total portfolio value of $1,160,007.02 up more than $41K from Thursday's total and is now within about $38K from the top.
Hey everyone, here's Jeff Mishlove with his latest round of contest stock picks. He seems to be doing pretty well with his picks. Are you? Here he is: As I reported in Friday’s blog, and earlier, Week 8 of the contest was a thrilling experience for me – as I ended up on the weekly leaderboard in second place – with a portfolio that appreciated 112.98% for the week.